Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis (Q38037648)

From Wikidata

Jump to navigation Jump to search

scientific article published on August 2012

Language	Label	Description	Also known as
English	Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis	scientific article published on August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

chronic myeloid leukemia

0 references

Simona Soverini

object named as

Simona Soverini

1

0 references

Gianantonio Rosti

3

object named as

Gianantonio Rosti

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Giovanni Martinelli

2

object named as

Giovanni Martinelli

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Michele Baccarani

5

object named as

Michele Baccarani

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Ilaria Iacobucci

4

object named as

Ilaria Iacobucci

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

publication date

1 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Pharmacogenomics

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

1271-1284

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Imatinib mesylate for the treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Crystal structure of the T315I mutant of AbI kinase

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Patterns of somatic mutation in human cancer genomes

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Clinical pharmacokinetics of imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Active transport of imatinib into and out of cells: implications for drug resistance

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

hOCT 1 and resistance to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

BCR-ABL kinase domain mutations in chronic myeloid leukemia: not quite enough to cause resistance to imatinib therapy?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Drug resistance in cancer: principles of emergence and prevention

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Assessment and follow-up of the proportion of T315I mutant BCR-ABL transcripts can guide appropriate therapeutic decision making in CML patients

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

The Bcr-Abl mutations T315I and Y253H do not confer a growth advantage in the absence of imatinib.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Conformational disturbance in Abl kinase upon mutation and deregulation

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Sequential development of mutant clones in an imatinib resistant chronic myeloid leukaemia patient following sequential treatment with multiple tyrosine kinase inhibitors: an emerging problem?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Three decades of transplantation for chronic myeloid leukemia: what have we learned?

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

ABL single nucleotide polymorphisms may masquerade as BCR-ABL mutations associated with resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

The Biology of CML blast crisis

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity

1 reference

https://api.crossref.org/works/10.2217%2FPGS.12.103

21 January 2018

Identifiers

10.2217/PGS.12.103

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

27 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38037648&oldid=1738262642"